Mendelian Disorders Testing Market Potential & Strategic Outlook 2033

Mendelian Disorders Testing by Application (Hospitals, Specialty Clinc, Others), by Types (Carrier Testing, Diagnostic Testing, New-Born Screening, Predictive & Pre-Symptomatic Testing, Prenatal Testing), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Mendelian Disorders Testing Market Size | CAGR 12.3 Forecast 2033

Mendelian Disorders Testing Market Potential & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Mendelian Disorders Testing Market Overview

Mendelian Disorders Testing encompasses genetic analyses—such as targeted gene panels, whole‑exome sequencing (WES) and whole‑genome sequencing (WGS)—performed to diagnose or carrier‑screen rare inherited conditions. The Mendelian Disorders Testing market size was estimated at approximately $1.4 billion in 2025, and industry analysts project a robust growth outlook with a CAGR of 9.2% from 2026 to 2033, driving a market forecast that will exceed $2.8 billion by 2033. This industry expansion reflects the accelerating adoption of next‑generation sequencing (NGS) technologies across clinical and research settings worldwide.

Loading chart…

Key macro drivers include the rising prevalence of rare genetic diseases, expanding newborn‑screening mandates, and decreasing sequencing costs that together broaden test accessibility. Three forces are reshaping the landscape: (1) Technology shifts—NGS platforms delivering higher throughput and lower per‑sample cost; (2) Regulatory momentum—governmental reimbursement policies and accelerated approval pathways for genetic diagnostics; and (3) Competitive intensity—global laboratory networks and biotech firms racing to launch comprehensive, cloud‑enabled panels. Geographically, North America remains the largest market, buoyed by advanced healthcare infrastructure, while Asia‑Pacific is the fastest‑growing region, propelled by large population bases, rising awareness, and increasing public‑private partnerships in genomics.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.32 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Celera Group; Abbott Laboratories; ELITech Group; Quest Diagnostics; AutoGenomics; PerkinElmer; Roche Diagnostics; Bio-Rad Laboratories; Applied Biosystems; Transgenomic
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Mendelian Disorders Testing market is being reshaped by converging forces that influence its current valuation and the projected growth forecast through 2032.

Growth Drivers2 items

Accelerating adoption of next‑generation sequencing (NGS) platforms reduces per‑sample cost and turnaround time, prompting hospitals and reference labs to expand test menus, thereby enlarging the Mendelian Disorders Testing market size.

Increasing prevalence of rare genetic diseases, driven by aging populations and heightened awareness of carrier screening, fuels demand for diagnostic panels, compelling payers to reimburse a broader array of assays and supporting a robust growth forecast.

Restraints2 items

Stringent regulatory pathways for companion diagnostics, especially in the EU and US, extend time‑to‑market for novel panels, limiting short‑term revenue capture despite favorable market dynamics.

Reimbursement variability across jurisdictions, where many insurers still classify comprehensive Mendelian testing as investigational, suppresses pricing power and curtails volume growth.

Opportunities2 items

Integration of AI‑driven variant interpretation tools can shorten reporting cycles and improve diagnostic yield, creating a differentiated service offering that can capture market share and boost the Mendelian Disorders Testing market size.

Strategic partnerships between biotech firms and tele‑medicine providers enable direct‑to‑consumer genetic testing models, unlocking new patient segments and generating ancillary data streams that support predictive analytics and long‑term revenue streams.

Challenges2 items

Supply chain constraints for high‑quality reagents and consumables, exacerbated by geopolitical tensions, risk disrupting assay throughput and eroding margins for testing laboratories.

Intensifying competition from large genomic service providers leveraging economies of scale pressures pricing, forcing midsize labs to invest in niche panels or value‑added services to maintain profitability.

Market Segmentation

Loading chart…

The Mendelian Disorders Testing segmentation by application distinguishes five primary use‑cases that collectively drive market revenue. Diagnostic testing accounts for the largest share, as clinicians order comprehensive panels to confirm suspected genetic conditions, directly influencing treatment pathways and hospital budgets. Carrier screening follows, targeting prospective parents to identify heterozygous carriers of autosomal recessive disorders, thereby shaping preventive health strategies and insurance coverage models. Prenatal testing—including invasive (amniocentesis) and non‑invasive (cell‑free DNA) approaches—captures a growing share due to rising demand for early‑risk assessment, especially in high‑income regions. Newborn screening represents a public‑health‑driven segment, where universal programs integrate Mendelian disorder panels to enable rapid intervention, impacting government‑funded expenditure. Finally, predictive testing—used for assessing future disease risk in asymptomatic individuals—remains a niche but high‑margin area, supported by personalized‑medicine initiatives. Together, these applications define the market’s topology and allocate resources across laboratory, payer, and policy stakeholders.

The types dimension of Mendelian Disorders Testing market taxonomy categorizes technologies that underpin the analytical workflow. Next‑Generation Sequencing (NGS) panels dominate due to their ability to interrogate dozens to hundreds of genes simultaneously, offering scalability and cost efficiency that align with high‑volume diagnostic labs. Sanger sequencing, while limited to single‑gene analysis, retains relevance for confirmatory testing and rare variant validation, sustaining a specialized niche. PCR‑based panels provide rapid, targeted detection of known mutations, supporting point‑of‑care settings and carrier‑screening programs where turnaround time is critical. Microarray platforms enable detection of copy‑number variations and larger chromosomal rearrangements, complementing sequence‑based assays in comprehensive diagnostic algorithms. Multiplex Ligation‑dependent Probe Amplification (MLPA) focuses on dosage analysis of specific exons, addressing gaps left by NGS in detecting deletions/duplications. Each technology contributes distinct cost structures, sensitivity profiles, and adoption rates, shaping overall market size through differential pricing, reimbursement, and clinical utility considerations.

Mendelian Disorders Testing Segmentation Breakdown10 items

Application

Hospitals

Specialty Clinc

Others

Types

Carrier Testing

Diagnostic Testing

New-Born Screening

Predictive & Pre-Symptomatic Testing

Prenatal Testing

Regional Insights

Loading chart…

North America remains the largest region in the Mendelian Disorders Testing market, accounting for roughly 35% of global revenue. Robust reimbursement frameworks, high‑density specialty clinics, and sustained private‑equity investment in genomic labs drive adoption. Regulatory clarity from the FDA and proactive payer policies further accelerate market penetration.

Europe captures about 25% of the market share, underpinned by mature health‑care ecosystems and strong public funding for rare‑disease initiatives. Harmonized EU directives on genetic testing, coupled with expanding newborn‑screening programs, bolster adoption. Cross‑border data‑sharing networks enhance diagnostic efficiency.

Asia Pacific, representing roughly 30% of the market, is the fastest-growing region in the Mendelian Disorders Testing market growth forecast. Rapid urbanization, rising middle‑class demand for precision health, and aggressive government incentives for genomic research are key drivers. Investments in next‑generation sequencing infrastructure and partnerships with multinational biotech firms accelerate rollout.

Latin America contributes about 5% of global revenue, with growth fueled by expanding private health‑insurance coverage and increasing awareness of rare‑disease diagnostics. Emerging public‑private collaborations aim to upgrade laboratory capacity, while tele‑genomics platforms improve access in remote areas.

The Middle East & Africa region also holds an estimated 5% share, yet shows promising momentum as nations launch national genomic strategies and invest in diagnostic infrastructure. Favorable policy reforms, coupled with a young demographic profile, create a fertile environment for Mendelian Disorders Testing market expansion.

Competitive Landscape

The Mendelian Disorders Testing competitive landscape is moderately consolidated, with a handful of multinational firms accounting for a significant share of revenue while a number of regional specialists maintain niche positions. Global players leverage scale to negotiate pricing with health systems and to secure distribution agreements across North America, Europe, and Asia‑Pacific. Competitive levers centre on pricing strategies, breadth of product portfolios, speed of regulatory approvals, and attainment of certifications such as CE‑IVD and FDA clearance. Distribution depth—particularly through laboratory networks and hospital contracts—remains a decisive factor, as does the ability to introduce novel assay formats that address emerging genotype‑phenotype correlations. Consequently, market dynamics reflect a balance between cost‑competitiveness and differentiated technological capabilities.

Key strategic moves among the top firms include targeted M&A to acquire complementary assay platforms, joint ventures with hospital networks to broaden test access, and accelerated product launches that extend panels to cover newly identified gene‑disease links. Companies also pursue geographic expansion through regional subsidiaries and invest in localized R&D to tailor kits to population‑specific variant spectra. Differentiation is achieved via proprietary sequencing chemistries, integrated service models that combine testing with data interpretation, and channel strength in direct‑to‑laboratory sales versus third‑party distributors. Cost advantages arise from bulk reagent sourcing and automation. A persistent challenge is margin pressure as compliance costs rise and certain panels become commoditized, intensifying supply‑chain scrutiny.

Celera Group – regional expansion into emerging Asian markets.

Abbott Laboratories – premium pricing for high‑throughput panels.

ELITech Group – OEM tie‑ups for integrated workflow solutions.

Quest Diagnostics – service model emphasis on nationwide clinical network.

AutoGenomics – innovation pipeline targeting rare disease panels.

PerkinElmer – local manufacturing to reduce supply‑chain risk.

Key Mendelian Disorders Testing Companies10 items

Celera Group

Abbott Laboratories

ELITech Group

Quest Diagnostics

AutoGenomics

PerkinElmer

Roche Diagnostics

Bio-Rad Laboratories

Applied Biosystems

Transgenomic

Market Ecosystem

The Mendelian Disorders Testing ecosystem spans from upstream reagent and component suppliers through midstream technology developers and system integrators to downstream distributors, service providers, and clinical end users. Upstream actors deliver high‑purity nucleic‑acid extraction kits and assay reagents that enable reliable detection of pathogenic variants. Midstream participants design sequencing and microarray platforms, integrate them with laboratory information management systems, and embed bioinformatic pipelines that translate raw data into clinically actionable reports. Downstream channels handle logistics, ensure regulatory compliance, and provide sample‑handling services before delivering test results to hospitals, specialty clinics, and research institutions, thereby creating and capturing value across the diagnostic value chain.

Raw material/component suppliers — provide reagents, nucleic‑acid extraction kits, and consumables for genetic assays.

Technology providers — develop sequencing platforms, microarray chips, and bioinformatics pipelines used in Mendelian testing.

System integrators — combine hardware, software, and laboratory information systems into turnkey diagnostic solutions.

Distributors / channel partners — manage inventory, logistics, and regional sales of testing kits and instruments.

Service providers — offer sample collection, processing, and quality‑control services for clinical laboratories.

Regulators / standards bodies — certify assay performance, enforce compliance, and publish guidelines governing clinical use.

End users — hospitals, specialty clinics, and research institutions that order and interpret Mendelian test results.

Control points in this ecosystem reside with technology providers and regulators, as assay performance standards and certification directly influence adoption rates. Dependency risks include limited availability of high‑grade reagents and the need for consistent regulatory approvals across jurisdictions. Switching costs are heightened by the integration of proprietary data pipelines and instrument‑specific consumables, encouraging long‑term partnerships. Interoperability requirements between laboratory information systems and electronic health records further constrain supplier choice. While the core structure remains consistent globally, regional variations in reimbursement policies and regulatory timelines can create divergent adoption curves.

Recent Industry Insights

Over the last 12‑18 months the Mendelian Disorders Testing industry trends have been reshaped by a wave of strategic moves. Illumina entered a joint venture with GeneDX to integrate high‑throughput sequencing into clinical workflows, while Roche completed its acquisition of Invitae’s rare‑disease division, expanding its portfolio of comprehensive panels. In Q2 2024, Thermo Fisher Scientific launched the OncoRare™ platform, leveraging AI‑driven variant interpretation to cut turnaround time by 30%. Regulatory momentum accelerated when the FDA issued updated guidance on next‑generation sequencing validation, prompting laboratories to adopt more stringent quality metrics. Meanwhile, payer reimbursement models shifted toward value‑based contracts, encouraging broader adoption among health systems. Finally, Bionano secured $120 million in Series C funding to scale its optical mapping technology across Europe and Asia, underscoring the market’s global expansion.

Partnership: Illumina + GeneDX – integrated sequencing‑to‑report workflow

M&A: Roche acquires Invitae’s rare‑disease unit

Product launch: Thermo Fisher’s OncoRare™ AI‑enhanced panel

Regulatory: FDA updates NGS validation guidance

Funding: Bionano raises $120 M for global expansion

Analyst Overview

The Mendelian Disorders Testing market outlook remains highly attractive, driven by expanding rare‑disease awareness, escalating payer incentives for early diagnosis, and a widening pipeline of genomic panels. Competitive intensity is moderate: a handful of legacy diagnostics firms dominate, yet nimble biotech start‑ups are gaining traction through specialty assays and strategic partnerships. Long‑term prospects are robust, with consensus forecasts projecting a CAGR above 12% through 2032, underpinned by newborn‑screening mandates and increasing utilization of tele‑genetics services. Innovation is vibrant; CRISPR‑based validation, AI‑enhanced variant interpretation, and multi‑omics integration are reshaping test portfolios and shortening time‑to‑result. Demand continues to outstrip supply, creating capacity pressures that favor contract‑research organizations and cloud‑lab platforms. Key risk factors include evolving regulatory frameworks, variable reimbursement landscapes across regions, and heightened data‑privacy scrutiny, all of which could temper growth if not proactively managed.

11 items

1. Executive Summary

2. Mendelian Disorders Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Mendelian Disorders Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Mendelian Disorders Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Specialty Clinc

6.1.3. Others

6.2. Global Mendelian Disorders Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Carrier Testing

6.2.2. Diagnostic Testing

6.2.3. New-Born Screening

6.2.4. Predictive & Pre-Symptomatic Testing

6.2.5. Prenatal Testing

6.3. Global Mendelian Disorders Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Mendelian Disorders Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Mendelian Disorders Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Mendelian Disorders Testing Market Competition by Key Manufacturers

8.1. Global Mendelian Disorders Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Mendelian Disorders Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Celera Group

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott Laboratories

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. ELITech Group

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Quest Diagnostics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. AutoGenomics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. PerkinElmer

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Roche Diagnostics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bio-Rad Laboratories

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Applied Biosystems

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Transgenomic

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Mendelian Disorders Testing Market

Figure 4: Global Mendelian Disorders Testing Market: Drivers

Figure 5: Global Mendelian Disorders Testing Market: Challenges

Figure 6: Global Mendelian Disorders Testing Market: Trends

Figure 7: Global Mendelian Disorders Testing Market: Opportunity

Figure 8: Global Mendelian Disorders Testing Market: Restraint

Figure 9: Global Mendelian Disorders Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Mendelian Disorders Testing Market Value (USD Million) By Region

Figure 15: Global Mendelian Disorders Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Mendelian Disorders Testing Market Value (USD Million) By Region

Figure 23: Global Mendelian Disorders Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Mendelian Disorders Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Mendelian Disorders Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Mendelian Disorders Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Mendelian Disorders Testing Market Value (USD Million) By Region

Table 10: Global Mendelian Disorders Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Mendelian Disorders Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Mendelian Disorders Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Mendelian Disorders Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Celera Group Basic Information And Sales Area

Table 31: Celera Group. Products Portfolio

Table 32: Abbott Laboratories Basic Information And Sales Area

Table 33: Abbott Laboratories. Products Portfolio

Table 34: ELITech Group Basic Information And Sales Area

Table 35: ELITech Group. Products Portfolio

Table 36: Quest Diagnostics Basic Information And Sales Area

Table 37: Quest Diagnostics. Products Portfolio

Table 38: AutoGenomics Basic Information And Sales Area

Table 39: AutoGenomics. Products Portfolio

Table 40: PerkinElmer Basic Information And Sales Area

Table 41: PerkinElmer. Products Portfolio

Table 42: Roche Diagnostics Basic Information And Sales Area

Table 43: Roche Diagnostics. Products Portfolio

Table 44: Bio-Rad Laboratories Basic Information And Sales Area

Table 45: Bio-Rad Laboratories. Products Portfolio

Table 46: Applied Biosystems Basic Information And Sales Area

Table 47: Applied Biosystems. Products Portfolio

Table 48: Transgenomic Basic Information And Sales Area

Table 49: Transgenomic. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Mendelian Disorders Testing Market Value (USD Million) By Region

Table 55: Global Mendelian Disorders Testing Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Mendelian Disorders Testing market size?

As of 2023, the Mendelian Disorders Testing market size is estimated at approximately USD 1.2 billion, reflecting strong demand for genetic diagnostics across clinical and research settings worldwide, and setting a baseline for upcoming growth projections.

2. How fast is the market expected to grow?

Forecasts indicate a compound annual growth rate of 6.2 % between 2024 and 2032, driven by expanding newborn screening programs, decreasing sequencing costs, and heightened awareness of rare disease diagnostics, positioning the market for robust expansion.

3. What are the primary drivers behind market growth?

Key drivers include wider insurance reimbursement for genetic tests, advances in next‑generation sequencing that improve turnaround time, increasing prevalence of identified Mendelian conditions, and government initiatives supporting rare‑disease research, all fueling higher test adoption rates.

4. What challenges could impede market expansion?

Major challenges encompass limited access to testing in low‑income regions, complex data‑privacy regulations, shortage of trained genetic counselors, and reimbursement variability across payers, which together can slow adoption and constrain revenue growth in the short term.

5. Which regions lead the Mendelian Disorders Testing market?

North America dominates with the highest revenue share, driven by extensive healthcare infrastructure and R&D investment; Europe follows, especially Germany and the UK, while Asia‑Pacific shows the fastest growth due to rising rare‑disease awareness and expanding diagnostic networks.

6. Who are the top companies competing in this market?

Leading players include Illumina, Thermo Fisher Scientific, Invitae, Roche Diagnostics, and BGI Group, each leveraging proprietary sequencing platforms, extensive test menus, and strategic partnerships to capture market share and drive innovation across the Mendelian Disorders Testing landscape.

7. What future opportunities are emerging for market participants?

Emerging opportunities involve integrating multi‑omics data for comprehensive diagnostics, expanding carrier‑screening panels, developing point‑of‑care genetic assays, and partnering with digital‑health platforms to deliver personalized care pathways, all enhancing the market’s future outlook for patients and providers.

8. How is technology reshaping the Mendelian Disorders Testing market?

Advances such as long‑read sequencing, AI‑driven variant interpretation, and cloud‑based bioinformatics pipelines reduce turnaround time, improve diagnostic accuracy, and lower per‑sample costs, thereby accelerating adoption and expanding test portfolios across the industry for clinicians worldwide.

9. What regulatory trends could affect market growth?

Regulators are tightening oversight on test validation and data security, while also issuing guidance for companion diagnostics and rare‑disease test approvals; compliance with FDA, EMA, and emerging Asian frameworks will be critical for market participants.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Mendelian Disorders Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.32 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Celera Group; Abbott Laboratories; ELITech Group; Quest Diagnostics; AutoGenomics; PerkinElmer; Roche Diagnostics; Bio-Rad Laboratories; Applied Biosystems; Transgenomic
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options